30 August 2006

Interim results for the six months to 30 June 2006

Cyprotex PLC (LSE:CRX), the drug discovery technology and information company, today reports its Interim Results for the half year ended 30 June 2006.

• Improving trade and working capital management has resulted in Cyprotex becoming cash flow positive during the first six months of 2006. Cash resources rose to £0.86m, from £0.69m at the end of 2005.

• Revenues increased by approximately 16% to £1.62m (1H 2005: £1.40m).

• Gross profits rose by over 16% to £1.41m (1H 2005: £1.22m).

• Gross margin, at 87%, was stable compared with the same period last year.

• Basic loss per share declined to 0.23p (1H 2005: 0.37p*).

• The rapid expansion of the Group’s customer base accelerated further as a result of the marketing drive from its expanded sales force and greater penetration in the United States.

*Restated following the adoption of FRS20 on 1 January 2006

Commenting on the results, Robert Morrisson Atwater, Chairman and Chief Executive Officer of Cyprotex PLC, said: “Cyprotex is a high technology company with exceptional operational gearing. We expect the benefits of the US sales and marketing drive implemented in recent months to be seen in the coming months.”

For further information:

Cyprotex PLC
Robert Morrison Atwater, Chief Executive Officer
Tel: +44 1625 505 100
ir@cyprotex.com
www.cyprotex.com

Noumura Code Securities Limited
Charles Walker
Tel: +44 20 7776 1206
cew@codesecurities.com
www.codesecurities.com